This book focuses on current research and methodologies developed for re-engineering cancer clinical trials and also for "hot" areas in drug development trials such as adaptive design, seamless Phase 2-3 trials, and personalized medicine using biomarkers. Background statistical methodology is summarized in the Appendix.